References for Part 1 of Over Dose: The Case Against the Drug Companies

1. Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacology Bulletin, 1988; 24(1):183-188.

2. Louie, AK, Lewis, TB, Lannon, MD. Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry, 1993;54(1):435-438.

3. Lazarou J; Pomeranz BH; Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta?analysis of prospective studies [see comments]. JAMA, 1998 Apr 15, 279(15):1200?5.

4. Ibid.

5. Gilman, AG, Rall, TW, Nies, AS, Taylor, P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergammon Press, 1990 and 1996.

6. Kolata, G. (New York Times News Service). Who cares when our drugs fail? San Diego Union-Tribune, Weds., Oct. 15, 1997: E-1,5.

7. Melmon, K.L., Morrelli, H.F., Hoffman, B.B., & Nierenberg, D.W. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. (3rd Edition). New York: McGraw-Hill, Inc., 1993.

8. Moore TJ; Psaty BM; Furberg CD. Time to act on drug safety. JAMA, 1998 May 20, 279(19):1571?3.

9. Cullen DJ; Bates DW; Small SD; Cooper JB; Nemeskal AR; Leape LL. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Joint Commission Journal on Quality Improvement, 1995 Oct, 21(10):541?8.

10. Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA, 1998 Apr 15, 279(15):1216?7.

11. Dickinson, JG. FDA seeks to double effort on confusing drug names. Dickinson's FDA Review, March 2000; 7(3):13-14.

12. Marks L. "Not just a statistic": the history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s?1970s. Social Science and Medicine, 1999 Nov, 49(9):1139?55.
[12A. Snider, S. The Pill: 30 Years of Safety Concerns. U.S. Food and Drug Administration, Dec. 1990; FDA Website.]

13. Van Hoften C; Burger H; Peeters PH; Grobbee DE; Van Noord PA; Leufkens HG. Long?term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. International Journal of Cancer, 2000;87(4):591?4.

14. Burke, W. Oral Contraceptives and Breast Cancer. JAMA, Oct. 11, 2000; 284:1837-38.

15. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstetrics and Gynecology, 1995 May, 85(5 Pt 1):793?801.

16. Bagshaw, S. The Combined Oral Contraceptive. Drug Safety, 1995; 12:91-96.

17. Ettinger B. Personal perspective on low?dosage estrogen therapy for postmenopausal women. Menopause, 1999; 6(3):273?6.

18. Weinstein L. Efficacy of a continuous estrogen?progestin regimen in the menopausal patient. Obstetrics and Gynecology, 1987;69(6):929?32.

19. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics and Gynecology, 1998;92(6):982?8.

20. Ettinger B. op cit.

21. American Society of Hospital Pharmacists. American Hospital Formulary Service, Drug Information 1999. Gerald K. McEvoy, Editor. Bethesda: 1999.

22. American Medical Association. AMA Drug Evaluations, Annual 1993. Chicago: American Medical Association, 1993.

23. Lindsay R; Hart DM; Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics and Gynecology, 1984;63(6):759?63.

24. Ettinger B. A practical guide to preventing osteoporosis. Western Journal of Medicine, 1988;149(6):691?5.

25. Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R. Menopausal estrogen and estrogen?progestin replacement therapy and breast cancer risk. Jama, 2000 Jan 26, 283(4):485?91.

26. Persson I; Weiderpass E; Bergkvist L; Bergstrom R; Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen?progestin replacement. Cancer Causes and Control, 1999 Aug, 10(4):253?60.

27. Peck, C., Barr, W., Benet, L., Collins, J., Desjardins, R., Furst, D., et al. Opportunities for integrating of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Journal of Clinical Pharmacology, 1994; 34:111-9.

28. Peck CC. Drug development: improving the process. Food Drug Law Journal, 1997; 52:163-7.

29. Woosley, RL. Drug Labeling Revisions -- Guaranteed to Fail? JAMA, Dec. 20, 2000; 284(23):3047-49.

30. Sussman, N. More Questions Than Answers. Primary Psychiatry, 2000; 7:6.

31. Angell, M. The Pharmaceutical Industry -- To Whom Is It Accountable? New England Journal of Medicine, 2000; 342:1902-4.

32. Melmon et al., op. cit.

33. Bowman, L. 51% Of U.S. Adults Take 2 Pills or More a Day, Survey Reports (Scripps Howard News Service). San Diego Union-Tribune, Weds., Jan. 17, 2001:A8.

34. Cullen et al., op. cit.

35. Gilman et al., op. cit.

36. Cohen JS; Insel PA. The Physicians' Desk Reference. Problems and possible improvements. Archives of Internal Medicine, 1996; 156(13):1375?80.

37. Cohen, JS. Adverse drug effects, compliance, and the initial doses of antihypertensive drugs recommended by the Joint National Community vs. the Physicians' Desk Reference. Archives of Internal Medicine, 2001;161:880-85.

38. Cohen, JS. Dose Discrepancies between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events. Archives of Internal Medicine, April 9, 2001: Scheduled for Publication.

39. Cohen, J.S. Ways To Minimize Adverse Drug Reactions: Individualized Doses and Common Sense Are Key. Postgraduate Medicine, Sept. 1999; 106: 163-72.

40. Cohen, JS. Adverse Drug Reactions: Effective Low-Dose Therapies for Older Patients. Geriatrics, Feb. 2000; 55(2):54-64.

41. Cohen, JS. Comparison of FDA Reports of Patient Deaths Associated with Sildenafil (Viagra) and with Injectable Alprostadil. Annals of Pharmacotherapy, March 2001;35:285-88.

42. Cohen, JS. Is the Product Information on Sildenafil (Viagra) Adequate to Facilitate Optimal Therapeutics and to Minimize Adverse Events? Annals of Pharmacotherapy, March 2001;35:337-42.

43. Cohen, JS. Should Patients Be Given a Low Test Dose of Viagra Initially? Drug Safety, July 2000; 23:1-10.

44. Rennie, D. Fair Conduct and Fair Reporting of Clinical Trials. JAMA, 1999; 282:1766-68.

45. Bodenheimer, T. Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. New England Journal of Medicine, 2000; 342:1539-44.

46. Huston, P. Redundancy, Disaggregation, and the Integrity of Medical Research. Lancet, 1996, Apr. 13;347(9007):1024-26.

47. Bodenheimer, op. cit.

48. Hotz, RL. Secrecy is often the price of medical research funding. Los Angeles Times, May 18, 1999; A-2, 21.

49. Angell, M. Is Academic Medicine for Sale? New England Journal of Medicine, May 18, 2000; 342:1516-18:

50. Ibid.

51. Sussman, op. cit.

52. Wazana, A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA, 2000; 283(3):373?80.

53. Physicians' Desk Reference, 54th Edition. Montvale, N.J.: Medical Economics Company, 2000.

Return to Part 1 of Over Dose: The Case Against the Drug Companies